Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

  • STATUS
    Recruiting
  • End date
    Nov 19, 2026
  • participants needed
    1000
  • sponsor
    University of Wisconsin, Madison
Send
Updated on 19 May 2025
See if I qualify
Accepts healthy volunteers

Summary

1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.

Description

Age-related macular degeneration (AMD) is a leading cause of blindness in the world. The early and intermediate stages of AMD progress to late stage resulting in vision loss due to either geographic atrophy or neovascular AMD. Preventive measures to reduce treatment burden and prevent blindness are important. While there are no approved therapies for early disease, active research is underway. However, advancing therapeutic trials for AMD prevention remains challenging due to the lack of primary care involvement in early-stage AMD diagnosis.

A clear need exists for a reliable screening tool, deployable in optometry or primary care facilities to identify those with an early stage of disease. While an Artificial Intelligence (AI) based screening tool would be an ideal solution, there are obstacles to its prospective validation due to difficulty in enrolling sufficient cases in a screening environment. A key step towards promoting this field lies in collecting a diverse dataset of multimodal imaging and providing a reference standard level 1 classification from a wide array of patients with AMD. Having such a benchmark dataset available for research purposes will empower the development and validation of AI models for AMD. This data can serve as the much-sought pathway to the rapid development of screening models, facilitating the referral of patients with the appropriate disease spectrum, and ultimately leading to the prevention of late AMD.

This is a prospective, cross-sectional, multi-center, observational study to collect and develop a meticulously curated and diverse AMD benchmark dataset, featuring reference standard level 1 classification and comprehensive annotation of images.

Study procedures include:

  • Patient history: demographics (age, sex, ethnicity, race), smoking history, family history of AMD
  • Physical exam: height and weight
  • Snellen best-corrected visual acuity (BCVA)
  • AMD classification (Beckman scale)

Eligible participants will undergo one retinal imaging session of both eyes for the following:

  • Single field stereo color fundus photography (cFP) - pre and post dilation
  • Macular spectral domain-optical coherence tomography (SD-OCT)

Due to the need for diversity in the dataset, sites need to represent a wide array of geographical locations. In addition, balancing will be done on enrolled participants with or without AMD including age, sex, and AMD level (worse eye selected as study eye).

Details
Condition Age-Related Macular Degeneration
Age 50years or above
Clinical Study IdentifierNCT06924021
SponsorUniversity of Wisconsin, Madison
Last Modified on19 May 2025

Eligibility

 Yes No Not Sure

Inclusion Criteria

Participants greater than or equal to 50 years of age at time of signing Informed Consent Form
Willing to comply with all study procedures and sign the Informed Consent Form (ICF)
Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center

Exclusion Criteria

Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed
Unable to acquire adequate quality images, as evaluated by the Central Reading Center
Severe vision loss requiring urgent surgery
Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light
A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study
Unwilling to sign informed consent form
Currently or previously enrolled in an interventional AMD clinical trial
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Accepts healthy volunteers

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.